Результаты поиска

Patient-reported pain severity and health-related quality of life in patients with multiple myeloma in real world clinical practice.

BACKGROUND: The association between patient self-reported pain severity and health-related quality-of-life (HRQoL) is poorly understood. AIMS: This real-world study of symptomatic multiple myeloma (MM) patients sought to determine how pain severity from a single question asked during routine clinical consultation was associated with HRQoL. METHODS AND RESULTS: Point-in-time data on HRQoL of 330 patients with MM (median age 70 years) receiving anti-myeloma therapy in Germany and Italy from November 2017 through February 2018 were analyzed. HRQoL was assessed using validated questionnaires (Wo

Совпадение в полном тексте источника
… Patient‐reported data. b Response to one or more EORTC QLQ‐MY20 questions 31, 32, 33, or 35 on bone aches/pain or site‐specific pain. c Patients may have reported bone pain in one or more sites. d Patients may have received more than one different type of bone health agent. e Bone health agents include denosumab …

Knowledge of Dental Students and Practitioners About Medication-Related Osteonecrosis of the Jaw in the Central Region of Saudi Arabia.

BACKGROUND: Bisphosphonates (BPs) are often used in treating benign and malignant disorders. Medication-related osteonecrosis of the jaw (MRONJ) is a significant problem that arises from the long-term use of BPs. OBJECTIVE: In this study, we assessed the knowledge of students and dentists about MRONJ in the central region of Saudi Arabia. METHODS: A cross-sectional study was conducted to collect information from dental students and practitioners from the central region of Saudi Arabia. A valid, reliable, and structured questionnaire was used to gather data using a non-probability convenient

Совпадение в полном тексте источника
… Bevacizumab (Avastin, Roche, Basel, Switzerland) | 7% (8) | 10.3% (14) | 0.288 Denosumab (Xgeva and Prolia, Amgen, Thousand Oaks, California, United States) | 13.2% (15) | 20.6% (28) Sirolimus (Rapamune, Pfizer, New York, New York, United States) | 2.6% (3) | 4.4% (6) Sorafenib (Nexavar, Bayer, Berlin …

The Synthetic Collagen-Binding Peptide NIPEP-OSS Delays Mouse Myeloma Progression.

Multiple myeloma (MM) is the second most common hematological malignancy. It is a clonal B-cell disorder characterized by the proliferation of malignant plasma cells in the bone marrow, the presence of monoclonal serum immunoglobulin, and osteolytic lesions. An increasing amount of evidence shows that the interactions of MM cells and the bone microenvironment play a significant role, suggesting that these interactions may be good targets for therapy. The osteopontin-derived collagen-binding motif-bearing peptide NIPEP-OSS stimulates biomineralization and enhances bone remodeling dynamics. Due

Совпадение в полном тексте источника
… MMBD treatments aim at maintaining patients’ current status rather than healing, by for example using bisphosphonates and denosumab, a humanized monoclonal antibody directed against RANKL [ 46 ]. …

Histopathological findings affect quantitative values of single photon emission computed tomography in patients with antiresorptive agent-related osteonecrosis of the jaws.

OBJECTIVES: This study investigated the relationships between quantitative values calculated from bone single photon emission computed tomography/computed tomography (SPECT/CT) images and histopathological findings observed in surgical specimens from patients with antiresorptive agent-related osteonecrosis of the jaw (ARONJ); it sought to clarify histopathological factors that cause accumulation in bone SPECT/CT images of patients with ARONJ. METHODS: This study included 81 pathological specimens of 21 lesions obtained from 18 patients with ARONJ who underwent SPECT/CT and jaw resection. The

Совпадение в полном тексте источника
… Intraindividual comparison of preoperative (99m)Tc-MDP SPECT/CT and intraoperative and histopathological findings in patients with bisphosphonate- or denosumab-related osteonecrosis of the jaw. J Craniomaxillofac Surg 2015; 43: 1461–1469. 15. Miyashita H, Shiba H, Kawana H, Nakahara T. …

Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis.

BackgroundRenal failure is a severe complication of symptomatic myeloma, related to higher mortality. Recovery from dialysis dependence can lead to enormous survival benefits. We investigated the effect factors for probability of dialysis independence.MethodsRetrospective data on 45 newly diagnosed MM (NDMM) patients with serious renal impairment and requiring hemodialysis were analyzed. The statistical methods including logistic regression analysis, Kaplan-Meier survival curves, the log-rank test and the Cox proportional hazards model for survival analysis were used in our study.ResultsTwenty

Совпадение в полном тексте источника
… Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk. 2014;14:e207‐211. 24. Pandit SR, Vesole DH. Management of renal dysfunction in multiple myeloma. Curr Treat Options Oncol. 2003;4:239‐246. 25. …

Multidisciplinary treatment system for bone metastases for early diagnosis, treatment and prevention of malignant spinal cord compression.

Malignant spinal cord compression (MSCC) is a serious complication of cancers. The present study aimed to establish a multidisciplinary treatment system for urgent magnetic resonance imaging (MRI) and referral to orthopedists in order to prevent neurological deficits caused by MSCC. In the present study, the extent to which this system achieved early diagnosis and treatment and prevented MSCC-caused neurological deficits was examined. The records from patients with neurological deficits caused by MSCC before (between April 2007 and March 2012; group A) and after (between April 2012 and March 2

Совпадение в полном тексте источника
… Furthermore, the rate of referral to orthopedists for neurological deficits before treatment and the use of bone-modifying agents (BMAs), such as denosumab or zoledronic acid were evaluated in groups A and B. …

The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer.

PurposeThe ZOTECT study assesses the effect of zoledronic acid (ZOL) on bone-marker levels and potential correlations with disease outcomes in bisphosphonate-naive patients.MethodsThis prospective, single-arm, open-label study in bisphosphonate-naive (≥6 months) patients with bone metastases from prostate cancer (PC; n=301) or breast cancer (BC; n=99) enrolled at 98 German sites (May 2006 to July 2008) investigated the effect of ZOL (4 mg intravenously every 4 weeks×4 months, with a final follow-up at 12 months) on bone-marker levels. Secondary assessments: skeletal-related event (SRE) rate, p

Совпадение в полном тексте источника
… Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–822. doi: 10.1016/S0140-6736(10)62344-6. 11. Lipton A., Cook R., Saad F., Major P., Garnero P., Terpos E. …

A comprehensive review on pain: Model, target, therapy, and prospect (Review).

Pain serves as both a protective physiological response essential for species survival and a global health issue affecting human well‑being and societal development. The present review systematically summarized and analyzed the research progresses on pain through a multidimensional analytical framework encompassing animal models, molecular targets, therapeutic approaches and future prospects. In animal modeling, neuropathic pain paradigms have evolved from traditional mechanical compression to composite models that combine dynamic displacement and chemical stimulation. Cancer‑induced pain mode

Совпадение в полном тексте источника
… Denosumab Denosumab, a monoclonal antibody targeting RANKL, suppresses osteoclast activation, reduces bone resorption, and increases bone density ( 209 ). … Compared with zoledronic acid, denosumab delays first SRE onset, reduces recurrence risk and improves controlled bone metastasis progression in breast, prostate and solid tumors ( 210 ). Advantages included renal safety without monitoring requirements. …

Lung cancer immunotherapy: progress, pitfalls, and promises.

Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading to relapse. Immunotherapy is profoundly altering the approach to cancer treatment owing to its tolerable safety profile, sustained therapeutic response due to immunological memory generation, and effectiveness across a broad patient population. Different tumor-specific vaccination strategies are

Совпадение в полном тексте источника
… Bioactivity Monoclonal Antibodies (MABs) | NSCLC | Cetuximab | Anti-EGFR Necitumumab | Anti-EGFR Nimotuzumab | Anti-EGFR Ficlatuzumab | Anti-EGFR Bevacizumab | Anti-VEGF Ramucirumab | Anti-VEGF/VEGFR2 Nivolumab | Anti-PD-1 Pembrolizumab | Anti-PD-1 Ipilimumab | Anti-CTLA-4 Tremelimumab | Anti-CTLA-4 Denosumab … Denosumab, an anti-RANKL (receptor activator of nuclear factor-kappa B ligand) mAb, showed efficacy in metastatic lung cancer inhibition in a phase III study [ 146 ]. …

Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.

Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM-MSCs exhibit abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing their tumor-promoting functions and prolonged osteoblast suppression. Here, we identify widespread DNA methylation alterations of bone marrow-isolated MSCs from distinct MM stages, particularly in Homeobox genes involved in osteogenic differentiation that associate with their aberrant expression. Moreover, these DNA methylation changes are recapitul

Совпадение в полном тексте источника
… Clinically approved bone-modifying agents for the treatment of MBD include bisphosphonates 56 , which inhibit bone resorption by suppressing OC activity, and denosumab 57 , a monoclonal antibody against the osteoclastogenic cytokine RANKL. … Raje N Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study Lancet Oncol. 2018 19 370 381 10.1016/S1470-2045(18)30072-X 29429912 58. …

The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma.

The study aims to investigate second primary malignancy (SPM) development and frailty in Turkish geriatric patients with multiple myeloma (MM) and to assess the relationship between overall survival (OS) and various characteristics including SPM and frailty. Seventy-two patients diagnosed with and treated for MM were enrolled in the study. Frailty was determined by the IMWG Frailty Score. Fifty-three participants (73.6%) were found to have clinically-relevant frailty. Seven patients (9.7%) had SPM. Median follow-up was 36.5 (22-48.5) months, and 17 patients died during the follow-up period. Ov

Совпадение в полном тексте источника
… Palliative radiotherapy, zoledronic acid, or denosumab were used for skeletal-related events. All patients received standard supportive care measures, including blood transfusions and prophylactic or therapeutic antibiotics according to guidelines. …

Epidemiology and reporting of osteoporotic vertebral fractures in patients with long-term hospital records based on routine clinical CT imaging.

UNLABELLED: Osteoporotic vertebral fractures signify an increased risk of future fractures and mortality and can manifest the diagnosis of osteoporosis. We investigated the prevalence of vertebral fractures in routine CT of patients with long-term hospital records. Three out of ten patients showed osteoporotic vertebral fractures (VFs) corresponding to the highest rates reported in European population-based studies. INTRODUCTION: VFs are a common manifestation of osteoporosis, which influences future fracture risk. Their epidemiology has been investigated in population-based studies. However,

Совпадение в полном тексте источника
… Moreover, bisphosphonates were the most consistently prescribed anti-osteoporotic drugs we could find in medical notes and, for instance, Denosumab was only prescribed in 3 patients. Therefore, we only calculated statistics for bisphosphonates. …

Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis.

Background: Previous studies have preliminarily identified the non-inferior efficacy for reducing skeletal-related event (SRE) rates between de-escalated (Q12w) and standard (Q3-4w) bone-targeting agents therapy in malignant tumor patients with bone metastases. In this study, we aim to make further efforts to analyze whether the de-escalated bisphosphonates (BPs) strategy is a suitable option by comprehensively retrieving and synthesizing state-of-the-art evidence. Methods: An extensive electronic search for randomized controlled trials (RCTs) comparing a BPs standard strategy with the de-esca

Совпадение в полном тексте источника
… Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer. (2016) 53:75–83. 10.1016/j.ejca.2015.09.011 39. Mulcahy LE, Curtin CM, McCoy RJ, O'Brien FJ, Taylor D, Lee TC, et al. …

PTH1R-CaSR Cross Talk: New Treatment Options for Breast Cancer Osteolytic Bone Metastases.

Metastatic breast cancer (BrCa) is currently incurable despite great improvements in treatment of primary BrCa. The incidence of skeletal metastases in advanced BrCa occurs up to 70%. Recent findings have established that the distribution of BrCa metastases to the skeleton is not a random process but due to the favorable microenvironment for tumor invasion and growth. The complex interplay among BrCa cells, stromal/osteoblastic cells, and osteoclasts in the osseous microenvironment creates a bone-tumor vicious cycle (a feed-forward loop) that results in excessive bone destruction and progressi

Совпадение в полном тексте источника
… Medical treatment with bisphosphonate (zeledronate) and RANKL inhibitor (denosumab) failed to lower the elevated serum calcium level. …

Current Advancements in the Diagnosis and Treatment of Metastatic Spinal Cord Compression and Its Postintervention Care: A Comprehensive Review.

Malignant spinal cord compression (MSCC) is a serious oncological emergency that can result in neurological impairment and significant pain. It is associated with high morbidity, mortality, and a decrease in quality of life. This review reviews the current literature concerning diagnosis, guidelines, timely intervention, and management options in oncology patients with MSCC. A literature search of PubMed using relevant keywords and MeSH terms yielded 604 articles. Of these, 31 studies met the predefined inclusion criteria and were selected for detailed data extraction and synthesis into a narr

Совпадение в полном тексте источника
… Besides, bone-modifying agents (BMAs), such as zoledronate and denosumab, have been evidenced to delay bone disease events and, in some cases, improve survival rate; specifically, zoledronate has been shown to reduce the rate of bone pathological fractures [ 26 ]. …

Трабковая аттенуляция L1 у взрослых пациентов с множественной миеломой: исследование с целью наблюдения за изображением низкодозволенной КТ.

Цель этого исследования заключалась в оценке воздействия трабекулярного сглаживания позвоночного тела L1 в низкодозированной КТ у взрослых пациентов с множественной миеломой (ММ), парящей множественной миеломой (ШМ) и моноклональной гаммопатией неопределенного значения (МГУС). МАТЕРИАЛЫ И МЕТОДЫ. 22 пациентов с MGS и 51 последовательные пациенты с новым диагнозом MM (SMM, n = 21; симптоматическая MM, n = 36). Сканирование КТ проводилось с использованием 128-slice Сканер КТ (Somatom go.Top, Siemens, Мюнхен, Германия). Сканирование всего тела с низкой дозой проводилось в одно время для каждого п

Совпадение в полном тексте источника
… Computed Tomography Density Changes of Bone Metastases after Concomitant Denosumab Skelet. Radiol. 2023 52 1567 1575 10.1007/s00256-023-04326-3 36961572 19. Graffy P.M. Lee S.J. Ziemlewicz T.J. Pickhardt P.J. …

MicroRNAs and Osteolytic Bone Metastasis: The Roles of MicroRNAs in Tumor-Induced Osteoclast Differentiation.

Osteolytic bone metastasis frequently occurs in the later stages of breast, lung, and several other cancers. Osteoclasts, the only cells that resorb bone, are hijacked by tumor cells, which break down bone remodeling systems. As a result, osteolysis occurs and may cause patients to suffer bone fractures, pain, and hypercalcemia. It is important to understand the mechanism of bone metastasis to establish new cancer therapies. MicroRNAs are small, noncoding RNAs that are involved in various biological processes, including cellular differentiation, proliferation, apoptosis, and tumorigenesis. Mic

Совпадение в полном тексте источника
… For example, combination treatments with miRNAs and currently approved osteoclast-targeting agents, such as bisphosphonates and the anti-RANKL antibody denosumab, might provide enhanced clinical efficiency. …

Multiple influence of immune cells in the bone metastatic cancer microenvironment on tumors.

Bone is a common organ for solid tumor metastasis. Malignant bone tumor becomes insensitive to systemic therapy after colonization, followed by poor prognosis and high relapse rate. Immune and bone cells in situ constitute a unique immune microenvironment, which plays a crucial role in the context of bone metastasis. This review firstly focuses on lymphatic cells in bone metastatic cancer, including their function in tumor dissemination, invasion, growth and possible cytotoxicity-induced eradication. Subsequently, we examine myeloid cells, namely macrophages, myeloid-derived suppressor cells,

Совпадение в полном тексте источника
… Denosumab is a fully human IgG2 monoclonal antibody that specifically targets RANKL. … Safety and efficacy of denosumab for fibrous dysplasia of bone. N Engl J Med. (2023) 388:766–8. doi: 10.1056/NEJMc2214862. 177. Omata D, Munakata L, Maruyama K, Suzuki R. Ultrasound and microbubble-mediated drug delivery and immunotherapy. …

Бремя костных заболеваний не влияет на общее выживание вновь диагностированных пациентов с множественной миеломой - единый центр, ретроспективный анализ изображений 119 Пациенты.

Множественная миелома (ММ) часто вызывает миеломное заболевание костей (МБД), проявляющееся в остеолитических повреждениях и событиях, связанных с скелетами (СР), что существенно снижает качество жизни и повышает заболеваемость. Низкая доза для всего тела (WBLDT) стала стандартом для оценки участия костей в диагностике, однако ее прогнозируемое значение остается неясным. Цель этого исследования состояла в том, чтобы оценить нагрузку МБМР на вновь диагностированных пациентов ММ с использованием WBLDT и изучить связи между характеристиками изображений и результатами выживаемости.МЕТОДЫ: В этом р

Совпадение в полном тексте источника
… Novel anti-myeloma agents have shown a favorable effect on markers of bone metabolism, whereas bone targeted therapies including bisphosphonates and denosumab prevent SREs [ [20] , [21] , [22] , [23] , [24] , [25] , [26] ]. …